The Chhattisgarh health department is reinforcing its commitment to stringent quality control measures. In a recent development, M/s. Effi Parenterals has been served with a show-cause notice that may result in the company being blacklisted. This follows the discovery of significant quality issues in the supplied medicines.
The CGMSCL ensures that all drug batches supplied to health institutions undergo rigorous quality testing through NABL-accredited laboratories. This process is designed to guarantee that only drugs meeting the required standards are distributed.
Specifically, the drugs in question are Albendazole Tablets IP 400 mg (Drug Code – D12), with the following batches: PGT25451, PGT25450, PGT25480, and PGT25229. These batches were tested at the State Drug Testing and Research Laboratory, Raipur, before being distributed to hospitals. The tests revealed that these batches did not meet the required quality standards. In response, the firm has received a show-cause notice, indicating potential blacklisting, consistent with the department’s zero-tolerance policy on quality. The firm has also been instructed to recall the failed batches from its warehouses.
Previously, the firm had supplied 14 batches of Albendazole Tablets IP 400 mg, which were approved for distribution after passing the NABL tests.